LB-P8
- Generic Name
- LB-P8
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
LB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (Leuconostoc citreum).
- Associated Conditions
- -
- Associated Therapies
- -
Top 10 liver disease stories of 2024
In 2024, Liver Disease News highlighted key liver disease research and treatments, including Rezdiffra's petition in Canada, a US MASLD study, Phase 3 trials for efruxifermin, patents for CM-101, FDA fast track for LB-P8, CRMA-1001's promise, Rezdiffra's Phase 3 success, ASO 56's potential, tirzepatide's MASH treatment, and bepirovirsen's fast track status for hepatitis B.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath